GLA
PTGX icon

Great Lakes Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Great Lakes Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.98M Sell
56,904
-14,139
-20% -$1.48M 0.05% 183
2026
Q1 		$7.49M Sell
71,043
-2,923
-4% -$259K 0.06% 177
2025
Q4 		$6.46M Sell
73,966
-15,205
-17% -$1.24M 0.05% 197
2025
Q3 		$5.92M Sell
89,171
-50,220
-36% -$2.85M 0.05% 224
2025
Q2 		$7.7M Sell
139,391
-12,927
-8% -$620K 0.06% 226
2025
Q1 		$7.37M Buy
152,318
+90,371
+146% +$3.79M 0.07% 223
2024
Q4 		$2.39M Sell
61,947
-7,678
-11% -$335K 0.02% 457
2024
Q3 		$3.13M Sell
69,625
-23,854
-26% -$964K 0.03% 421
2024
Q2 		$3.24M Sell
93,479
-3,681
-4% -$108K 0.03% 405
2024
Q1 		$2.81M Buy
97,160
+6,007
+7% +$163K 0.02% 428
2023
Q4 		$2.09M Sell
91,153
-50,406
-36% -$882K 0.02% 454
2023
Q3 		$2.36M Sell
141,559
-5,489
-4% -$107K 0.02% 439
2023
Q2 		$4.06M Sell
147,048
-3,436
-2% -$86K 0.04% 367
2023
Q1 		$3.46M Buy
+150,484
New +$2.53M 0.03% 427

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Great Lakes Advisors's PTGX Position: Q2 2026 in Review

Great Lakes Advisors reduced its Protagonist Therapeutics (PTGX) stake by 20% in Q2 2026, selling an estimated $1.48M and leaving 56,904 shares worth $6.98M. The position accounts for 0.05% of the portfolio, ranked #183.

Great Lakes Advisors first reported a position in PTGX in Q1 2023 and has held it in 14 quarters since. The position peaked at $7.7M in Q2 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Great Lakes Advisors held 56,904 shares of Protagonist Therapeutics worth $6.98M as of Q2 2026.
  • Great Lakes Advisors sold 14,139 Protagonist Therapeutics shares in Q2 2026, an estimated $1.48M.
  • Protagonist Therapeutics made up 0.05% of Great Lakes Advisors's portfolio in Q2 2026, its #183 holding.
  • Great Lakes Advisors first reported a position in Protagonist Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Great Lakes Advisors's Protagonist Therapeutics position peaked at $7.7M in Q2 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.